ALX Oncology announces common stock, warrants offering

ALX Oncology Holdings announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants in this offering will be sold by ALX Oncology. ALX Oncology intends to use the net proceeds from the offering to fund ongoing development of evorpacept, including clinical trials targeting market expansion, and for working capital and general corporate purposes. Piper Sandler and Cantor are acting as the joint book-running managers for the proposed offering.